Anti-inflammatory Function of High-Density Lipoproteins via Autophagy of IκB Kinase

Cellular and Molecular Gastroenterology and Hepatology

Volumn 1, Issue 2, 2015, Pages 171-187.e1

  Gerster, Ragam ^a,b   Eloranta, Jyrki J ^a   Hausmann, Martin ^a   Ruiz, Pedro A ^a   Cosin Roger, Jesus ^a,c   Terhalle, Anne ^a   Ziegler, Urs ^a   Kullak Ublick, Gerd A ^a,b   von Eckardstein, Arnold ^b,d   Rogler, Gerhard ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF VALENCIA   (Spain)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Apolipoprotein A I; Autophagy; Inflammatory Bowel Disease; NF B

Indexed keywords

APOLIPOPROTEIN A1; DEXTRAN SULFATE; HIGH DENSITY LIPOPROTEIN; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; INTRACELLULAR ADHESION MOLECULE PROTEIN; MYELOPEROXIDASE; PROTEIN; SMALL INTERFERING RNA; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; WORTMANNIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; COLON MUCOSA; COLONOSCOPY; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; ELECTRON MICROSCOPY; ENZYME PHOSPHORYLATION; EXPERIMENTAL COLITIS; FEMALE; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE MICROSCOPY; INTESTINE EPITHELIUM CELL; LUCIFERASE ASSAY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; WEIGHT REDUCTION; WESTERN BLOTTING; WILD TYPE MOUSE;

EID: 84928940302     PISSN: None     EISSN: 2352345X     Source Type: Journal    
DOI: 10.1016/j.jcmgh.2014.12.006     Document Type: Article

References (65)

1. Fisher E.A., Feig J.E., Hewing B., et al. High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2012, 32:2813-2820.
2. Lee-Rueckert M., Blanco-Vaca F., Kovanen P.T., et al. The role of the gut in reverse cholesterol transport-focus on the enterocyte. Prog Lipid Res 2013, 52:317-328.
3. Ono K. Current concept of reverse cholesterol transport and novel strategy for atheroprotection. JCardiol 2012, 60:339-343.
4. Rosenson R.S., Brewer H.B., Davidson W.S., et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 2012, 125:1905-1919.
5. Sorci-Thomas M.G., Thomas M.J. High density lipoprotein biogenesis, cholesterol efflux, and immune cell function. Arterioscler Thromb Vasc Biol 2012, 32:2561-2565.
6. Mineo C., Shaul P.W. Novel biological functions of high-density lipoprotein cholesterol. Circ Res 2012, 111:1079-1090.
7. Gordon S.M., Davidson W.S. Apolipoprotein A-I mimetics and high-density lipoprotein function. Curr Opin Endocrinol Diabetes Obes 2012, 19:109-114.
8. Filippatos T.D., Elisaf M.S. High density lipoprotein and cardiovascular diseases. World J Cardiol 2013, 5:210-214.
9. Patel P.J., Khera A.V., Wilensky R.L., et al. Anti-oxidative and cholesterol efflux capacities of high-density lipoprotein are reduced in ischaemic cardiomyopathy. Eur J Heart Fail 2013, 15:1215-1219.
10. Annema W., von Eckardstein A. High-density lipoproteins. Circ J 2013, 77:2432-2448.
11. Von Eckardstein A., Sibler R.A. Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2. Curr Opin Lipidol 2011, 22:26-32.
12. Demarin V., Lisak M., Morovic S., et al. Low high-density lipoprotein cholesterol as the possible risk factor for stroke. Acta Clin Croat 2010, 49:429-439.
13. Morton J., Ng M.K., Chalmers J., et al. The association of high-density lipoprotein cholesterol with cancer incidence in type ii diabetes: a case of reverse causality?. Cancer Epidemiol Biomarkers Prev 2013, 22:1628-1633.
14. Jafri H., Alsheikh-Ali A.A., Karas R.H. Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. JAm Coll Cardiol 2010, 55:2846-2854.
15. Yaari S., Goldbourt, Even-Zohar S., Neufeld H.N. Associations of serum high density lipoprotein and total cholesterol with total, cardiovascular, and cancer mortality in a 7-year prospective study of 10 000 men. Lancet 1981, 1:1011-1015.
16. Colin S., Briand O., Touche V., et al. Activation of intestinal peroxisome proliferator-activated receptor-alpha increases high-density lipoprotein production. Eur Heart J 2013, 34:2566-2574.
17. Lutton C., Champarnaud G. Cholesterol synthesis and high density lipoprotein uptake are regulated independently in rat small intestinal epithelium. Gut 1994, 35:343-346.
18. Sappati Biyyani R.S., Putka B.S., Mullen K.D. Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease. JClin Lipidol 2010, 4:478-482.
19. Williams H.R., Willsmore J.D., Cox I.J., et al. Serum metaboling profiling in inflammatory bowel disease. Dig Dis Sci 2012, 57:2157-2165.
20. Rogler G., Herold G., Fahr C., et al. High-density lipoprotein 3 retroendocytosis: a new lipoprotein pathway in the enterocyte (Caco-2). Gastroenterology 1992, 103:469-480.
21. Fielding C.J., Havel R.J., Todd K.M., et al. Effects of dietary cholesterol and fat saturation on plasma lipoproteins in an ethnically diverse population of healthy young men. JClin Invest 1995, 95:611-618.
22. Von Eckardstein A., Funke H., Walter M., et al. Structural analysis of human apolipoprotein A-I variants. Amino acid substitutions are nonrandomly distributed throughout the apolipoprotein A-I primary structure. JBiol Chem 1990, 265:8610-8617.
23. Saborowski M., Kullak-Ublick G.A., Eloranta J.J. The human organic cation transporter-1 gene is transactivated by hepatocyte nuclear factor-4α. JPharmacol Exp Ther 2006, 317:778-785.
24. Obermeier F., Kojouharoff G., Hans W., et al. Interferon-gamma (IFN-gamma)- and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice. Clin Exp Immunol 1999, 116:238-245.
25. Wirtz S., Neufert C., Weigmann B., et al. Chemically induced mouse models of intestinal inflammation. Nat Protoc 2007, 2:541-546.
26. Becker C., Fantini M.C., Neurath M.F. High resolution colonoscopy in live mice. Nat Protoc 2006, 1:2900-2904.
27. Huang E.H., Carter J.J., Whelan R.L., et al. Colonoscopy in mice. Surg Endosc 2002, 16:22-24.
28. Becker C., Fantini M.C., Neurath M.F. High resolution colonoscopy in live mice. Nat Protoc 2007, 1:2900-2904.
29. Steidler L., Hans W., Schotte L., et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000, 289:1352-1355.
30. Frens G. Controlled nucleation for the regulation of the particle size in monodisperse gold suspensions. Nature Phys Sci 1973, 241:20-22.
31. Choi A.M., Ryter S.W., Levine B. Autophagy in human health and disease. NEngl J Med 2013, 368:651-662.
32. Nys K., Agostinis P., Vermeire S. Autophagy: a new target or an old strategy for the treatment of Crohn's disease?. Nat Rev Gastroenterol Hepatol 2013, 10:395-401.
33. Deretic V., Saitoh T., Akira S. Autophagy in infection, inflammation and immunity. Nat Rev Immunol 2013, 13:722-737.
34. Cooney R., Baker J., Brain O., et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 2010, 16:90-97.
35. Travassos L.H., Carneiro L.A., Ramjeet M., et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010, 11:55-62.
36. Kabeya Y., Mizushima N., Ueno T., et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000, 19:5720-5728.
37. Tanida I., Minematsu-Ikeguchi N., Ueno T., Kominami E. Lysosomal turnover, but not a cellular level, of endogenous LC3 is a marker for autophagy. Autophagy 2005, 1:84-91.
38. Scharl M., Wojtal K.A., Becker H.M., et al. Protein tyrosine phosphatase nonreceptor type 2 regulates autophagosome formation in human intestinal cells. Inflammatory Bowel Diseases 2012, 18:1287-1302.
39. Hampe J., Franke A., Rosenstiel P., et al. Agenome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2007, 39:207-211.
40. Rioux J.D., Xavier R.J., Taylor K.D., et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 2007, 39:596-604.
41. Raelson J.V., Little R.D., Ruether A., et al. Genome-wide association study for Crohn's disease in the Quebec Founder Population identifies multiple validated disease loci. Proc Natl Acad Sci USA 2007, 104:14747-14752.
42. Klionsky D.J. Crohn's disease, autophagy, and the Paneth cell. NEngl J Med 2009, 360:1785-1786.
43. Yano T., Kurata S. An unexpected twist for autophagy in Crohn's disease. Nat Immunol 2009, 10:134-136.
44. Cadwell K., Liu J.Y., Brown S.L., et al. Akey role for autophagy and the autophagy gene Atg16l1 in mouse andhuman intestinal Paneth cells. Nature 2008, 456:259-263.
45. Saitoh T., Fujita N., Jang M.H., et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1β production. Nature 2008, 456:264-268.
46. Stephens N.A., Kieft R., Macleod A., Hajduk S.L. Trypanosome resistance to human innate immunity: targeting Achilles' heel. Trends Parsitol 2012, 28:539-545.
47. Gordon S.M., Hofmann S., Askew D.S., Davidson W.S. High density lipoprotein: it's not just about lipid transport anymore. Trends Endocrinol Metab 2011, 22:9-15.
48. Besler C., Lüscher T.F., Landmesser U. Molecular mechanisms of vascular effects of high-density lipoprotein: alterations in cardiovascular disease. EMBO Mol Med 2012, 4:251-268.
49. Murphy A.J., Westerterp M., Yvan-Charvet L., Tall A.R. Anti-atherogenic mechanisms of high density lipoprotein: effects on myeloid cells. Biochim Biophys Acta 2012, 1821:513-521.
50. Drew B.G., Rye K.-A., Duffy S.J., et al. The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol 2012, 8:237-245.
51. Van Deventer S.J.H. Targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease-the mechanisms of action of infliximab. Aliment Pharmacol Ther 1999, 13(Suppl 4):3-8. 38.
52. Kontoyiannis D., Pasparakis M., Pizarro T.T., et al. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999, 10:387-398.
53. Targan S.R., Hanauer S.B., van Deventer S.J.H., et al. Ashort-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. NEngl J Med 1997, 337:1029-1036.
54. Lichtenstein G.R., Abreu M.T., Cohen R., et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006, 130:940-987.
55. Besler C., Heinrich K., Rohrer L., et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. JClin Invest 2011, 121:2693-2708.
56. Robbesyn F., Garcia V., Auge N., et al. HDL counterbalance the proinflammatory effect of oxidized LDL by inhibiting intracellular reactive oxygen species rise, proteasome activation, and subsequent NF-κB activation in smooth muscle cells. FASEB J 2003, 17:743-745.
57. Cuzzocrea S., Dugo L., Patel N.S., et al. High-density lipoproteins reduce the intestinal damage associated with ischemia/reperfusion and colitis. Shock 2004, 21:342-351.
58. Di Bartolo B.A., Nicholls S.J., Bao S., et al. The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins. Atherosclerosis 2011, 217:395-400.
59. Wang Y., Zhu X., Wu G., et al. Effect of lipid-bound apoA-I cysteine mutants on lipopolysaccharide-induced endotoxemia in mice. JLipid Res 2008, 49:1640-1645.
60. Vanhollebeke B., Pays E. The trypanolytic factor of human serum: many ways to enter the parasite, a single way to kill. Mol Microbiol 2010, 76:806-814.
61. Pays E., Vanhollebeke B. Human innate immunity against African trypanosomes. Curr Opin Immunol 2009, 21:493-498.
62. Pérez-Morga D., Vanhollebeke B., Paturiaux-Hanocq F., et al. Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. Science 2005, 309:469-472.
63. Wan G., Zhaorigetu S., Liu Z., et al. Apolipoprotein L1, a novel Bcl-2 homology domain 3-only lipid-binding protein, induces autophagic cell death. JBiol Chem 2008, 283:21540-21549.
64. Mizumura K., Choi A.M., Ryter S.W. Emerging role of selective autophagy in human diseases. Front Pharmacol 2014, 5:244.
65. Muller C., Salvayre R., Nègre-Salvayre A., et al. HDLs inhibit endoplasmic reticulum stress and autophagic response induced by oxidized LDLs. Cell Death Differ 2011, 18:817-828.